Serum Antibodies for Diagnosis of Inflammatory Bowel Disease
Customize your policy alerts
Sign up for all eocco policy alerts
Know when eocco releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, coverage, and exclusions for serum antibody panels (eg, ASCA, ANCA and others), TPMT genetic/phenotypic testing, thiopurine metabolite monitoring, fecal lactoferrin, and measurement of therapeutic drug levels for diagnosis or management of inflammatory bowel disease for EOCCO members.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Baseline TPMT genotype testing (covered)
Covered when ANY of the following baseline indications are met (one time during patient's lifetime):
Covered one time during the patient's lifetime.
Monitoring thiopurine metabolites (covered)
Considered medically necessary for EITHER of the following monitoring indications:
Includes measurement of 6-thioguanine nucleotides (6-TGN) and 6-methylmercaptopurine ribonucleotides (6-MMRP)/6-MMPN as listed.
Tests considered experimental, investigational, or unproven (not covered)
The following tests are considered experimental/investigational for diagnosis, differentiation, or management of IBD:
Effectiveness for these indications has not been established; considered experimental/investigational and not covered for diagnosis, distinction of UC vs Crohn's, management of IBD, or other non-established indications.
Fecal lactoferrin
Coverage stance depends on indication:
Fecal lactoferrin is considered experimental/investigational for evaluation of infectious diarrhea, Clostridium difficile infection, and all other indications.
Tests listed in this policy as experimental, investigational, or unproven are excluded from coverage for diagnosis of inflammatory bowel disease (IBD), for distinguishing ulcerative colitis from Crohn’s disease, for management of IBD, and for all other indications where effectiveness has not been established. Examples include serologic antibody panels and related assays such as ASCA, ANCA, ACCA, ALCA, AMCA, Anti‑C, Anti‑L, OmpC, anti‑Cbir1, 12 antibodies, Prometheus IBD sgi, and ASMA (when used for IBD), as well as tests that measure antibodies or serum drug levels for biologic agents and similar panels.
Use of serologic antibody panels (for example, ASCA, ANCA, and other listed antibodies) and measurement of antibodies or serum drug levels to biologic agents (for example, assays for infliximab, adalimumab, vedolizumab, ustekinumab and branded panels such as Anser IFX/ADA/VDZ/UST) is considered experimental and investigational for diagnosing IBD, distinguishing ulcerative colitis from Crohn’s disease, or otherwise managing IBD because their effectiveness for these indications has not been established.
Billing and Coding
| 82630 | TPMT (thiopurine S-methyltransferase) gene analysis / enzyme activity (as listed in policy text) |
| 82657 | Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen (listed for TPMT) |
| 83630 | Lactoferrin, fecal; qualitative |
| 83631 | Lactoferrin, fecal; quantitative |
| 86256 | Fluorescent noninfectious agent antibody; titer, each antibody |
| 82397 | ACCA, ALCA, AMCA, Anti-C, Anti-L, ANCA, ASCA, OmpC, anti-Cbir-1, 12 antibodies, and ASMA (listed under not covered) |
| 83516 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen (listed under not covered) |
| 83518 | Immunoassay; qualitative or semi-quantitative; multiple step method (listed under not covered) |
| 83519 | Immunoassay; qualitative or semiquantitative, single step method (listed under not covered) |
| 83520 | Quantitative, by radioimmunoassay (eg, RIA) (listed under not covered) |
| 86021 | Immunoassay, analyte, quantitative; not otherwise specified (listed under not covered) |
| 86255 | Antibody identification; leukocyte antibodies / Fluorescent noninfectious agent antibody; screen, each antibody (listed under not covered) |
| 86671 | Antibody; fungus, not elsewhere specified (listed under not covered) |
| 88350 | Immunofluorescence, per specimen; each additional single antibody stain procedure (listed under not covered) |
Prior Authorization and Documentation Requirements
Prior authorization submission requirements
Prior authorization requests must include supporting clinical documentation to demonstrate medical necessity. Submit specialist chart notes, the ordering specialist's history and physical, results of colonoscopy and any other diagnostic studies performed, and the pathology report with the prior authorization request.
- Chart notes and history and physical from ordering specialist
- Results of colonoscopy and other diagnostic studies performed
- Pathology report
Prior authorization submission — completeness reminder
Include the full list of required supporting documents with the prior authorization; incomplete submission may delay review. Ensure chart notes, H&P, diagnostic study results, and pathology are attached as described in the policy.
- Attach ordering specialist chart notes and history & physical
- Attach results of colonoscopy and other diagnostic studies
- Attach pathology report
Required supporting documentation
Prior authorization requests should include the ordering specialist's chart notes and history and physical, results of colonoscopy and other diagnostic studies, and the pathology report to support the request.
- Chart notes and history and physical from ordering specialist
- Results of colonoscopy and other diagnostic studies performed
- Pathology report
Experimental/investigational tests — denial risk
Requests for ASCA, ANCA, ACCA, ALCA, AMCA, Anti-C, Anti-L, OmpC, anti‑Cbir1, Prometheus IBD sgi, ASMA (for IBD), and similar serologic antibody panels or measurement of antibodies/serum levels to biologics are considered experimental/investigational and may be denied.
- ASCA (anti‑Saccharomyces cerevisiae antibodies)
- ANCA (anti‑neutrophil cytoplasmic antibodies)
- ACCA, ALCA, AMCA
- Anti‑C, Anti‑L, OmpC, anti‑Cbir1
- Prometheus IBD sgi diagnostic test
- ASMA for IBD; measurement of antibodies/serum levels to biologics
Clinical Background
Inflammatory bowel disease (IBD) encompasses Crohn’s disease and ulcerative colitis; diagnosis relies primarily on radiographic, endoscopic, and histologic evaluation rather than serologic testing. Serologic markers such as ANCA and ASCA have been studied to help differentiate UC from CD but lack sufficient sensitivity and specificity to definitively establish the diagnosis. Approximately 10% of patients have indeterminate colitis, and serologic tests are not considered reliable enough to replace standard diagnostic approaches.
Test Definitions and Performance Characteristics
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.